Kailera Therapeutics (KLRA) vs Rapport Therapeutics (RAPP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kailera Therapeutics is the larger company by market cap ($1.51 billion vs $1.47 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KLRA | RAPP |
|---|---|---|
| Share price | $11.61 | $30.65 |
| Market cap | $1.51B | $1.47B |
| 1-day change | +16.10% | +2.68% |
| YTD return | — | +1.02% |
| 1-year return | — | +14.62% |
| EPS (TTM) | $-4.51 | $-3.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-111.48M |
| 52-week high | $28.23 | $52.93 |
| 52-week low | $9.76 | $23.75 |
| Distance from 52-week high | -58.87% | -42.09% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +265.20% | +105.68% |
| Average volume | 861.01K | 358.42K |
| Shares outstanding | 129.64M | 47.98M |
| Employees | 145 | 84 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kailera Therapeutics
KLRA stock →Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
About Rapport Therapeutics
RAPP stock →Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
KLRA vs RAPP FAQ
Which is bigger, Kailera Therapeutics or Rapport Therapeutics?
Kailera Therapeutics (KLRA) is larger, with a market capitalization of $1.51B compared with $1.47B for Rapport Therapeutics (RAPP).
Are Kailera Therapeutics and Rapport Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.